Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Not Confirmed
Not Confirmed
18-20 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Industry Trade Show
Not Confirmed
18-20 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
11 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/synaptogenix-announces-5-0-million-financing-302244690.html
18 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/synaptogenix-announces-new-collaboration-with-lsu-health-new-orleans-for-study-of-proprietary-analogs-in-spinal-cord-injury-302200323.html
26 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/synaptogenix-announces-fda-authorization-of-ind-application-for-clinical-trial-for-bryostatin-1-in-multiple-sclerosis-302182860.html
07 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/synaptogenix-applauds-dea-proposal-to-reclassify-cannabis-and-shares-expected-benefits-to-cannasoul-for-cannabinoid-based-drug-discovery-302137968.html
24 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/synaptogenix-regains-compliance-with-nasdaq-minimum-bid-price-requirement-for-continued-listing-302125770.html
09 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/synaptogenix-increases-stake-in-innovative-psilocybin-drug-discovery-company-through-its-partnership-with-cannasoul-analytics-302111691.html
Details:
Bryostatin-1 is a small molecule that works by activating protein kinase C enzymes. Currently, it is being evaluated as a potential treatment for multiple sclerosis.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Synaptogenix Announces FDA IND Authorization for Bryostatin-1 Trial in Multiple Sclerosis
Details : Bryostatin-1 is a small molecule that works by activating protein kinase C enzymes. Currently, it is being evaluated as a potential treatment for multiple sclerosis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 26, 2024
Details:
Under the partnership, Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications.
Lead Product(s): Cannabinoid-based Therapeutic
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Small molecule
Recipient: Cannasoul
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 02, 2023
Lead Product(s) : Cannabinoid-based Therapeutic
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Recipient : Cannasoul
Deal Size : $4.0 million
Deal Type : Partnership
Details : Under the partnership, Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 02, 2023
Details:
Bryostatin-1, a small molecule that works by activating protein kinase C, which is investigated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Bryostatin-1, a small molecule that works by activating protein kinase C, which is investigated for the treatment of amyotrophic lateral sclerosis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2023
Details:
The agreement aims to conduct a phase 1 trial of Bryostatin-1, a small molecule that works by activating protein kinase C, in multiple sclerosis (MS).
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Recipient: Cleveland Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 19, 2023
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Cleveland Clinic
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to conduct a phase 1 trial of Bryostatin-1, a small molecule that works by activating protein kinase C, in multiple sclerosis (MS).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 19, 2023
Details:
Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 16, 2022
Details:
Bryostatin-1 is a powerful protein kinase C (PKC) agonist, activating PKC isozymes at nanomolar concentrations. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Katalyst Securities
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 18, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Katalyst Securities
Deal Size : $15.0 million
Deal Type : Private Placement
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Details : Bryostatin-1 is a powerful protein kinase C (PKC) agonist, activating PKC isozymes at nanomolar concentrations. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndro...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 18, 2022
Details:
Bryostatin 1 is a natural product derived from a marine microorganism called Bugula neritina, for patients suffering from advanced and moderately severe Alzheimer's disease.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data
Details : Bryostatin 1 is a natural product derived from a marine microorganism called Bugula neritina, for patients suffering from advanced and moderately severe Alzheimer's disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2022
Details:
Bryostatin-1 is a small molecule that works by activating protein kinase C (PKC) in the brain. PKC is an enzyme that plays an important role in maintaining the health of synapses, which are the connections between neurons (nerve cells).
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Bryostatin-1 is a small molecule that works by activating protein kinase C (PKC) in the brain. PKC is an enzyme that plays an important role in maintaining the health of synapses, which are the connections between neurons (nerve cells).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2022
Details:
Preclinical studies have also demonstrated Bryostatin-1 regenerative mechanisms of action for the rare disease, as a treatment for Fragile X syndrome.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Synaptogenix to Present at the Cell Symposium
Details : Preclinical studies have also demonstrated Bryostatin-1 regenerative mechanisms of action for the rare disease, as a treatment for Fragile X syndrome.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2022
Details:
Bryostatin-1 caused highly significant cognitive enhancement for pre-specified patients who received Bryostatin-1 in absence of Namenda in our two previous, consolidated 3-month pilot trials, while the Placebo-treated patients showed no significant benefit.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial
Details : Bryostatin-1 caused highly significant cognitive enhancement for pre-specified patients who received Bryostatin-1 in absence of Namenda in our two previous, consolidated 3-month pilot trials, while the Placebo-treated patients showed no significant benef...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?